BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
GENERAL COMMENTS
Taking into account that all patients are minors, it is necessary to be more explicit in the instructions regarding the signing of informed consent according to the existing international regulations and above all those of the National Statement on Ethical 
This study protocol (randomised, placebo-controlled) is a important step towards standardization of ADHD treatment in NF1. There is only one point that I am concerned about. Previous studys showed a quite robust long-term effect of stimulants (MPH) on cognition in NF1 (Mautner et al. 2002) . This study protocol is limited to early effects only. This should be adressed or discussed somehow.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1
• Taking into account that all patients are minors, it is necessary to be more explicit in the instructions regarding the signing of informed consent according to the existing international regulations and above all those of the National Statement on Ethical Conduct in Human Research of the Australian Government National Health and Medical Research Council (update 2015 Chapter 4.2: Children and young people).
We thank the reviewer for this suggestion and have expanded the Ethical considerations section of the manuscript to the following (pages 22-23):
The study will be conducted in compliance with the guidelines for Good Clinical Practice and the Declaration of Helsinki and the National Health and Medical Research Committee National Statement on Ethical Conduct in Human Research. Written informed consent will be obtained from all participants before participation. During the informed consent process, a member of the research team will provide information about trial including but not limited to the study objectives, potential risks and benefits, inconveniences and the participants' rights and responsibilities. Any questions about the trial will be addressed in detail. As participants are minors, written informed consent will be obtained from their parent/legal guardian. In addition, a child-friendly written information sheet will be provided and verbal agreement for participation will be obtained from the child. Participation will only proceed if the child or adolescent agrees to participate in the research.
Reviewer 2
• This study protocol (randomised, placebo-controlled) is an important step towards standardization of ADHD treatment in NF1. There is only one point that I am concerned about. Previous study showed a quite robust long-term effect of stimulants (MPH) on cognition in NF1 (Mautner et al. 2002) . This study protocol is limited to early effects only. This should be adressed or discussed somehow.
As the reviewer points out, one previous study has examined the effect of stimulants on cognitive outcomes in NF1. Investigators used the Test of Variables of Attention (TOVA), demonstrating a large effect. While very promising data, the study was limited in a number of ways making an unbiased interpretation of the results difficult. For example, the trial was an open label unblinded study, participants were not randomised to different treatments and as such, was essentially uncontrolled. We agree that the 12 month assessment window was a positive design feature of that study and also acknowledge that the 6 week treatment period in our trial will preclude us from examining the effects of methylphenidate in more distal outcomes that will require longer-term follow-up, such as social functioning and academic achievement. As such, the following has been added to the Discussion section (page 24): To date, previous studies have reported a beneficial effect of MPH on ADHD symptoms in children with NF1,14,43 and the one trial that examined the effects of MPH on child-direct assessments, suggested a robust treatment response for attention over a 12 month period.14 To our knowledge, this is the first randomised controlled trial evaluating the effects of MPH on cognition in NF1 and will provide important evidence for the efficacy of MPH in treating deficits in attention, working memory and ADHD symptoms in children with NF1 over a six week period. Open-label extension studies will be required to determine longer-term effects on more distal outcomes such as social functioning, academic achievement and psychiatric comorbidities.
